inogatran manufacturers
- Inogatran
-
- $2120.00
-
2026-07-15
- CAS:155415-08-0
- Purity:
- Supply Ability: 10g
- Inogatran
-
- $2120.00
-
2026-07-14
- CAS:155415-08-0
- Purity:
- Supply Ability: 10g
- Inogatran
-
- $2120.00
-
2025-08-22
- CAS:155415-08-0
- Purity:
- Supply Ability: 10g
|
| | inogatran Basic information |
| Product Name: | inogatran | | Synonyms: | inogatran;H-314-27;Glycine, N-[(1R)-2-[(2S)-2-[[[3-[(aminoiminomethyl)amino]propyl]amino]carbonyl]-1-piperidinyl]-1-(cyclohexylmethyl)-2-oxoethyl]-;Inogatran (H-314-27);2-(((R)-3-cyclohexyl-1-((S)-2-((3-guanidinopropyl)carbamoyl)piperidin-1-yl)-1-oxopropan-2-yl)amino)acetic acid | | CAS: | 155415-08-0 | | MF: | C21H38N6O4 | | MW: | 438.56 | | EINECS: | | | Product Categories: | | | Mol File: | 155415-08-0.mol |  |
| | inogatran Chemical Properties |
| density | 1.36±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | Soluble in DMSO | | pka | 2.16±0.10(Predicted) |
| | inogatran Usage And Synthesis |
| Uses | Inogatran (H-314-27) is a synthetic thrombin inhibitor, developed for the possible treatment and prophylaxis of arterial and venous thrombotic diseases. | | in vivo | Inogatran (H-314-27; 0.075, 0.25, 0.75 mg/kg, i.v.) results in dose-dependent increases in activated partial thromboplastin time (aPTT), thrombin time (TT), and prothrombin time (PT) in a canine electrolytic injury model of venous thrombosis[1].
Inogatran dose-dependently inhibits thrombus formation, which is measured as an increase in time to occlusion (TTO) and a decrease in thrombus weight. Inogatran also improves vena caval blood flow and reduces the overall incidence of thrombotic occlusion in a rat model[2]. | | References | [1] Ignasiak DP, et al. Effects of Intravenous Enoxaparin and Intravenous Inogatran in an Electrolytic Injury Model of Venous Thrombosis in the Dog. J Thromb Thrombolysis. 1998 Nov;6(3):199-206. DOI:10.1023/A:1008806312396
[2] Chi L, et al. Antithrombotic effect of LB-30057 (CI-1028), a new synthetic thrombin inhibitor, in a rabbit model of thrombosis: comparison with inogatran. J Thromb Thrombolysis. 2001 Feb;11(1):19-31. DOI:10.1023/a:1008900109285 |
| | inogatran Preparation Products And Raw materials |
|